TScan Completes Trial Enrollment, FDA Clears New Heme Drugs
Patients who fail to reach complete donor chimerism by month two after allogeneic transplant face a markedly higher relapse...
Jon Napitupulu
Aardvark Announces Voluntary Pause of Phase 3 HERO Trial
Aardvark Therapeutics has halted enrollment and dosing in its Phase 3 HERO trial and its open-label extension after reversible...
Cogent Highlights Bezuclastinib Summit Trial Data at AAAAI
Bezuclastinib delivered a mean −32.0-point reduction in total symptom score at 48 weeks in NonAdvanced systemic mastocytosis, a 56%...
First Participants Dosed in Scynexis’s SCY-247 Phase 1 Trial
SCYNEXIS has begun dosing in a Phase 1 single- and multiple-ascending dose study of its intravenous SCY-247, with initial...
Fractyl Trial Targets Post-GLP-1 Weight Maintenance
Fractyl Health has completed randomization in REMAIN-1, its sham-controlled pivotal cohort evaluating the Revita endoscopic procedure for weight maintenance...
First Patient Dosed in MindRank’s AI-Designed GLP-1 Trial
MindRank has dosed the first patient in MOBILE, a Phase III, multicenter, randomized, double-blind, placebo-controlled trial of its oral...
Ophirex Supplies Marimastat for Snakebite Treatment Study
Phase 2 platform funding of £4.2 million is backing TOCSINS, a multicountry trial evaluating oral snakebite therapies, with Ophirex...
MindRank’s Breakthrough AI GLP-1 Drug Enters Phase III Trial
MindRank has dosed the first patient in MOBILE, a Phase III, multicenter, randomized, double-blind, placebo-controlled trial of MDR-001, an...
New Hope: Stem Cell Trial Improves Age-Related Frailty
In a Phase 2b randomized, dose-finding study of 148 ambulatory adults with aging-related frailty, intravenous laromestrocel improved six-minute walk...
ITM Reveals New pNETs Analysis from COMPETE Trial at ENETS
Phase 3 COMPETE met its primary endpoint, with 177Lu-edotreotide delivering a clinically and statistically significant improvement in progression-free survival...